{"id":"NCT02021643","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","officialTitle":"A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-10","primaryCompletion":"2016-08-12","completion":"2016-11-03","firstPosted":"2013-12-27","resultsPosted":"2018-02-20","lastUpdate":"2018-02-20"},"enrollment":687,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic HCV Infection"],"interventions":[{"type":"DRUG","name":"Sofosbuvir","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":["Ribasphere®"]},{"type":"DRUG","name":"PEG","otherNames":["Pegasys®"]}],"arms":[{"label":"Sofosbuvir+RBV+PEG 12 weeks","type":"EXPERIMENTAL"},{"label":"Sofosbuvir+RBV 12 weeks","type":"EXPERIMENTAL"},{"label":"Sofosbuvir+RBV 16 weeks","type":"EXPERIMENTAL"},{"label":"Sofosbuvir+RBV 24 Weeks","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir (SOF)+ ribavirin (RBV), with or without Pegylated interferon alfa (Peg-IFNα-2a/ PEG)) in participants with chronic genotype (GT)-1, 2, 3, and 6 Hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF+PEG+RBV 12 Weeks (GT 1 and GT6)","deltaMin":95.5,"sd":null},{"arm":"SOF+RBV 12 Weeks (GT1 and GT6)","deltaMin":100,"sd":null},{"arm":"SOF+RBV 16 Weeks (GT1 and GT6)","deltaMin":100,"sd":null},{"arm":"SOF+RBV 24 Weeks (GT1 and GT6)","deltaMin":94.2,"sd":null},{"arm":"SOF+RBV 12 Weeks (GT2)","deltaMin":96.8,"sd":null},{"arm":"SOF+RBV 24 Weeks (GT3)","deltaMin":95.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":35,"countries":["China","Hong Kong","South Korea","Taiwan","Vietnam"]},"refs":{"pmids":["26503414","26864153","26835876"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":155},"commonTop":["Anaemia","Headache","Pyrexia","Upper respiratory tract infection","Fatigue"]}}